Asthma

Implications of Declining Asthma Exacerbation Rates During the COVID-19 Pandemic

By

Tori Rodriguez, MA, LPC, AHC

Asthma exacerbations dropped during the pandemic; what can be learned from this occurrence that may help lower exacerbation rates in the future?

Exploring Autoimmunity in Asthma: A Clinical Overview Plus Q&A

By

Britt Gambino

Although asthma and autoimmune disease are thought to have mutually exclusive pathogeneses, they both result from a dysregulated immune system.

National Asthma Education and Prevention Program: Focused Guideline Updates

By

Tori Rodriguez, MA, LPC, AHC

The National Asthma Education and Prevention Program published focused updates to their asthma management guidelines.

Biologic Use in Asthma: How Treatment Setting, Other Factors, Affect Adherence

By

Ron Goldberg

In patients with moderate to severe asthma using biologics, how does the treatment setting affect adherence — and what other factors affect adherence rates?

Montelukast and Neuropsychiatric Outcomes in Asthma and Allergic Rhinitis

By

Sheila Jacobs

Are patients with asthma and allergic rhinitis who initiate montelukast at higher risk for sleep and anxiety disorders?

Albuterol/Budesonide Fixed-Dose Combo Rescue Inhaler to Get FDA Review

By

Brian Park, PharmD

The NDA submission is supported by data from the phase 3 MANDALA trial, which included 3132 patients with moderate to severe asthma.

Early-Life Respiratory Tract Infections, School-Age Asthma, and Lung Function

By

Ron Goldberg

Do children with early-life respiratory tract infections have increased risk for chronic respiratory problems and asthma when they reach school age?

Reslizumab: Real-World Effect on Eosinophilic Asthma Exacerbations, OCS

By

Virginia A. Schad, PharmD, RPh

What is the real-world effectiveness of reslizumab in preventing eosinophilic asthma exacerbations, both in those switching biologic therapies and in biologic-naïve patients?